The Appropriate Anticoagulation Duration for Chronic Obstructive Pulmonary Disease With Pulmonary Thromboembolism
NCT ID: NCT03185845
Last Updated: 2017-06-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
392 participants
INTERVENTIONAL
2017-06-15
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Personalized Anticoagulant Therapy for Pulmonary Thromboembolism
NCT06341231
3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE
NCT00365950
A Prospective Study in Chinese Patients With Lower Extremity Ankle Fracture of Oral Anticoagulants to Prevent Venous Thromboembolism (VTE)
NCT04128254
Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD
NCT03277001
Protocol-based Management and Perioperative Outcomes in Patients With Chronic Antithrombotic Therapy
NCT04852406
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prolonged anticoagulation
3 months longer anticoagulation after regular treatment
Warfarin
tailored dose according to international normalized ratio (INR) for 3 months
Regular anticoagulation
stop anticoagulation after regular treatment
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Warfarin
tailored dose according to international normalized ratio (INR) for 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Regular anticoagulation for 3 months and got CT pulmonary angiography
Exclusion Criteria
* Patients need long term anticoagulation to treat other diseases
* Patients unwilling to receive prolonged anticoagulation
40 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jianguo He
Chief of Pulmonary Vascular Disease Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Chaoyang Hospital
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016YFC1304402B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.